Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Envoy Medical (COCH) EBIAT (2022 - 2025)

Envoy Medical's EBIAT history spans 4 years, with the latest figure at -$6.5 million for Q3 2025.

  • For Q3 2025, EBIAT fell 8.76% year-over-year to -$6.5 million; the TTM value through Sep 2025 reached -$22.1 million, down 4.96%, while the annual FY2024 figure was -$20.1 million, 32.89% up from the prior year.
  • EBIAT for Q3 2025 was -$6.5 million at Envoy Medical, down from -$5.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $1.6 million in Q3 2023 and bottomed at -$13.3 million in Q2 2023.
  • The 4-year median for EBIAT is -$5.0 million (2025), against an average of -$5.6 million.
  • The largest YoY upside for EBIAT was 216.73% in 2023 against a maximum downside of 979.05% in 2023.
  • A 4-year view of EBIAT shows it stood at -$11.5 million in 2022, then soared by 57.47% to -$4.9 million in 2023, then dropped by 1.07% to -$4.9 million in 2024, then plummeted by 31.4% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's EBIAT are -$6.5 million (Q3 2025), -$5.7 million (Q2 2025), and -$5.0 million (Q1 2025).